# Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic

> **NCT02503839** · PHASE1 · COMPLETED · sponsor: **Anne Margarita Dyrhol Riise** · enrollment: 39 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** etoricoxib
- **BIOLOGICAL:** H56:IC31

## Key facts

- **NCT ID:** NCT02503839
- **Lead sponsor:** Anne Margarita Dyrhol Riise
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2019-09
- **Final completion:** 2020-03-23
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2022-04-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02503839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02503839, "Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT02503839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*